Skip to main content
Log in

The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis

  • Original Research Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to describe the frequency and trends in prescriptions and recommendations for selective serotonin reuptake inhibitors (SSRIs) for mental health disorders in children and adolescents in Canada from 2005 to 2009.

Method

Data were extracted from databases supplied by IMS Brogan (IMS), a proprietary source of pharmacoepidemiologic data. Analyses were performed to obtain descriptive statistics on SSRI prescriptions dispensed, SSRI drug recommendation frequency, reasons for drug recommendations (therapeutic indication), and median duration of use of SSRIs in Canadian children. Canadian census data were used to assess whether changes in SSRI use were related to changes in the number of children in Canada over the time period studied.

Results

SSRI prescriptions written by pediatricians increased by 39 %, while SSRI drug recommendations by all specialists for children and adolescents increased by 44 % over the 5-year interval. Over the 5-year period studied, fluoxetine was the most commonly recommended and dispensed SSRI. The use of escitalopram has increased while the use of paroxetine has declined. Between 2005 and 2009, the two most common therapeutic indications for SSRI recommendations were mood disorder (50 %) and anxiety disorder (25 %). Median treatment duration was less than 1 year, with duration generally increasing with patient age.

Conclusions

The increase in use of SSRIs in Canadian children and adolescents from 2005 to 2009 suggests that the effects of public health warnings concerning suicidal thinking and behavior associated with these drugs are now dissipating. This may be attributable to the FDA’s pediatric approvals for fluoxetine and escitalopram, the growing comfort of clinicians with using SSRIs in children, limited availability of psychosocial treatments, and the influence of marketing. The use of paroxetine has continued to decline, likely because of specific warnings directed toward this agent and limited evidence supporting its efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. HealthCanada. Important drug safety information until further information is available, Paxil® (paroxetine hydrochloride) should not be used in children and adolescents under 18 years of age. 2003. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2003/paxil_hpc-cps-eng.php. Accessed 5 April 2011.

  2. Medicines CoSo. Safety of Seroxat (Paroxetine) in children and adolescents under 18 years-contraindication in the treatment of depressive illness. 2003. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2015704. Accessed 13 June 2011.

  3. Administration FaD. Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD). 2003. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm. Accessed 15 June 2011.

  4. Administration FaD. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. 2004. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm. Accessed 15 June 15 2011.

  5. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. [Erratum appears in CMAJ. 2008 May 20;178(11):1466]. CMAJ. 2008;178(8):1005–11.

    Article  PubMed  Google Scholar 

  6. Singh T, Prakash A, Rais T, Kumari N. Decreased use of antidepressants in youth after US Food and Drug Administration black box warning. Psychiatry (Edgmont). 2009;6(10):30–4.

    Google Scholar 

  7. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356–63.

    Article  PubMed  Google Scholar 

  8. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ. Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol. 2008;18(1):70–80.

    Article  PubMed  Google Scholar 

  9. Kurian BT, Ray WA, Arbogast PG, Fuchs DC, Dudley JA, Cooper WO. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. 2007;161(7):690–6.

    Article  PubMed  Google Scholar 

  10. Tournier M, Greenfield B, Galbaud du Fort G, et al. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res. 2010;179(1):57–63.

    Article  PubMed  Google Scholar 

  11. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884–91.

    Article  PubMed  Google Scholar 

  12. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65(1):94–101.

    Article  PubMed  Google Scholar 

  13. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66(6):633–9.

    Article  PubMed  Google Scholar 

  14. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health. 2007;97(4):750–4.

    Article  PubMed  Google Scholar 

  15. IMSHealth. http://www.imshealth.com/portal/site/ims.

  16. Yan J. FDA approves antidepressant for use in adolescents. Psychiatric News. 2009;44(9).

  17. Wijlaars LPMM, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012;7(3):e33181.

    Article  PubMed  CAS  Google Scholar 

  18. Hernandez JF, Mantel-Teeuwisse AK, van Thiel GJMW, et al. A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. PLoS One. 2012;7(9):e45515.

    Article  PubMed  CAS  Google Scholar 

  19. Wooltorton E. Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. CMAJ. 2003;169(5):446.

    PubMed  Google Scholar 

  20. Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45(6):709–19.

    Article  PubMed  Google Scholar 

  21. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006;16(1–2):59–75.

    Article  PubMed  Google Scholar 

  22. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205–15.

    Article  PubMed  Google Scholar 

  23. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031–7.

    Article  PubMed  CAS  Google Scholar 

  24. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807–20.

    Article  PubMed  CAS  Google Scholar 

  25. Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165(4):459–67.

    Article  PubMed  Google Scholar 

  26. Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1397–405.

    Article  PubMed  Google Scholar 

  27. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):773–9.

    Article  PubMed  CAS  Google Scholar 

  28. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415–23.

    Article  PubMed  Google Scholar 

  29. Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1622–32.

    Article  PubMed  Google Scholar 

  30. Safer DJ. Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders? Pediatrics. 2006;118(3):1248–51.

    Article  PubMed  Google Scholar 

  31. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004851.

  32. Usala T, Clavenna A, Zuddas A, Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2008;18(1):62–73.

    Article  PubMed  CAS  Google Scholar 

  33. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332–9.

    Article  PubMed  CAS  Google Scholar 

  34. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment—reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):580–7.

    Article  PubMed  CAS  Google Scholar 

  35. von Knorring A-L, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26(3):311–5.

    Article  Google Scholar 

  36. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–90.

    Article  PubMed  CAS  Google Scholar 

  37. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161(6):1079–83.

    Article  PubMed  Google Scholar 

  38. Alaghband-Rad J, Hakimshooshtary M. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry. 2009;18(3):131–5.

    Article  PubMed  Google Scholar 

  39. Carandang C, Jabbal R, Macbride A, Elbe D. A review of escitalopram and citalopram in child and adolescent depression. J Can Acad Child Adolesc Psychiatry. 2011;20(4):315–24.

    PubMed  Google Scholar 

  40. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):721–9.

    Article  PubMed  Google Scholar 

  41. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.

    Article  PubMed  CAS  Google Scholar 

  42. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–66.

    Article  PubMed  CAS  Google Scholar 

  43. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(1):4–8.

    Article  PubMed  CAS  Google Scholar 

  44. Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy Econ. 2002;5(1):3–19.

    PubMed  Google Scholar 

  45. Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioeth Inq. 2010;7(1):13–29.

    Article  Google Scholar 

Download references

Acknowledgements

This research was supported by a grant from the Canadian Institutes of Health Research.

The funding organization was not involved in the design, conduct, data collection, management, analysis or interpretation, or the preparation, review, or approval of the manuscript.

Dr. Patten was a paid member of a grant review panel for a Pfizer-sponsored funding competition in 2012. The remaining authors have no relevant conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tamara Pringsheim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lam, D., Gorman, D.A., Patten, S. et al. The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis. Pediatr Drugs 15, 319–327 (2013). https://doi.org/10.1007/s40272-013-0014-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-013-0014-8

Keywords

Navigation